NCT03159507 is a Phase 4 clinical trial of MAG-EPA in Healthy, sponsored by SCF Pharma.

Who is sponsoring NCT03159507?

NCT03159507 is sponsored by SCF Pharma.

What drugs are being tested in NCT03159507?

Interventions in NCT03159507: MAG-EPA.

Is NCT03159507 still recruiting?

NCT03159507 is currently completed. Last updated 4 April 2019.

Last reviewed 2019-04-04 · How we verify

NCT03159507

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Omega-3 Index on Cellular Metabolism and Quality of Life

Completed Phase 4 Last updated 4 April 2019

What this trial tests

Phase 4 trial testing MAG-EPA in Healthy in 16 participants. Completed in 14 March 2019.

Timeline

2 October 2017

Primary endpoint
14 March 2019

14 March 2019

Quick facts

Lead sponsor	SCF Pharma
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	16
Start date	2 October 2017
Primary completion	14 March 2019
Estimated completion	14 March 2019
Sites	1 location across Canada

Drugs / interventions tested

MAG-EPA

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

SCF Pharma

Who can join

19 and older, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Determine whether personal optimization of the Omega-3 index improves cellular metabolism and quality of life (according to the SF-36 form).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other SCF Pharma trials

Trials by the same sponsor.

NCT06155513 — Omega-3 Monoglyceride Based Topic Products as Skin Prebiotics for Eczema · NA · recruiting
NCT06219213 — Glyceryl Eicosapentaenoate Based Topic Products As an Irritant-free Cream and Serum for Hydration of Sensitive Skin · NA · recruiting
NCT04897893 — Impact of 2.0g Daily of MAG-EPA on the AA/EPA Ratio and Inflammation Biomarkers in a Healthy Population Aged of 50+. · Phase 4 · completed
NCT04159532 — Comparative Study of Three Different Formulations of Omega-3 (EPA+DHA) · Phase 4 · completed
NCT05161702 — Increased Inflammation-resolving Activity by Omega-3 Monoglycerides in Peripheral Blood Mononuclear Cells (PBMC). · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03159507 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SCF Pharma
Last refreshed: 4 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03159507.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing